

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/614,954	07/07/2003	Thomas M. Hohn	30884D	7143
75	590 02/11/2005		EXAM	INER
Larry W. Stults, Ph.D. Syngenta Biotechnology, Inc. 3054 Cornwallis Road		IBRAHIM, MEDINA AHMED		
			ART UNIT	PAPER NUMBER
Research Triangle Park, NC 27709			1638	

DATE MAILED: 02/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

-		Application No.	Applicant(s)			
Office Action Summary		10/614,954	HOHN ET AL.			
		Examiner	Art Unit			
		Medina A Ibrahim	1638			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
THE M - Extens after S - If the p - If NO p - Failure Any re	PRTENED STATUTORY PERIOD FOR REP MAILING DATE OF THIS COMMUNICATION sions of time may be available under the provisions of 37 CFR 101X (6) MONTHS from the mailing date of this communication. Seriod for reply specified above is less than thirty (30) days, a reperiod for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statuply received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	I. 1.136(a). In no event, however, may a reply be timely within the statutory minimum of thirty (30) days d will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1)⊠ F	1) Responsive to communication(s) filed on <u>05 December 2004</u> .					
2a) <u></u> □	This action is FINAL . 2b)⊠ Th	is action is non-final.				
•—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositio	on of Claims	•				
4 5)□ (6)⊠ (7)□ (4) Claim(s) 1-6 is/are pending in the application. 4a) Of the above claim(s) 6 is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1-5 is/are rejected. 7) Claim(s) is/are objected to.					
Application	on Papers					
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority ur	nder 35 U.S.C. § 119					
a)_ 1 2	cknowledgment is made of a claim for foreignal All b) Some * c) None of: 1. Certified copies of the priority documents. Certified copies of the priority documents. Copies of the certified copies of the priority documents. Copies of the certified copies of the priority documents. Copies of the certified copies of the priority documents. Copies of the certified copies of the priority documents. Copies of the certified copies of the priority documents. Copies of the certified copies of the priority documents. Cop	nts have been received. Ints have been received in Application or the contraction of the	on No ed in this National Stage			
Attachment(: 1) Notice 2) Notice 3) Informa		4) Interview Summary Paper No(s)/Mail Da	(PTO-413)			

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Applicant's response filed 11/15/04 in reply to the Office action mailed 08/13/04 has been entered. This Office action contains NEW GROUNDS OF REJECTIONS not necessitated by Applicant's amendments. Therefore, this action is non-final. The delay in applying these grounds of rejection is regretted.

Claims 1-6 are pending. Claims 1-5 are under consideration. Claim 6 drawn to the non-elected invention of the response of 07/23/04 has been withdrawn from consideration. A complete reply to this Official action must include cancellation of nonelected claim or other appropriate action (37 CFR 1.144). See MPEP § 821.01.

The terminal disclaimer filed on 11/15/04 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US 6,346,655 has been reviewed and is accepted. The terminal disclaimer has been recorded.

All previous objections and rejections not set forth below have been withdrawn in view of Applicant's amendment.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

⁽b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Application/Control Number: 10/614,954

Art Unit: 1638

Claims 1-5 are rejected under 35 U.S.C. 102(b) as being anticipated by Kimura et al (The Journal of Biological Chemistry, Vol. 273 (3), January 18 issue, pp. 1654-1661 (1998), Applicant's IDS).

The claims are directed to an isolated nucleic acid molecule comprising a nucleotide sequence that encodes SEQ ID NO: 6, the nucleotide sequence of SEQ ID NO: 5, a chimeric gene comprising a heterologous promoter operably linked to said nucleic acid molecule, and a transgenic host cell comprising the chimeric gene.

Kimura et al teach an isolated nucleic acid molecule from *Fusarium graminearum* encoding Trichothecene 3-0-acetyltransferase which appears to be the same as the claimed nucleotide sequence. Figure 4 on page 1659 shows the nucleic acid molecule comprising the sequence from nucleotide position 1 to nucleotide position 1356 which is 100% identical to SEQ ID NO: 5 (see attached Sequence Search Results). Kimura et al also teach a recombinant vector comprising a chimeric DNA construct comprising the isolated nucleic acid molecule under the control of a heterologous promoter, and transformed host cells expressing said chimeric gene (see page 1657, Figure 3; page 1658, column 1, last full paragraph). Therefore, Kimura et al teach all claim limitations. Applicant is reminded that the novelty of the invention of the claims in the issued patent of US 6,346,655 is the transgenic plant expressing the nucleic acid sequence (for example, SEQ ID NO: 5) and a method for producing said transgenic plant. The instantly rejected claims are not drawn to such a plant or method. Therefore, this rejection is proper.

Application/Control Number: 10/614,954

Art Unit: 1638

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Medina A. Ibrahim whose telephone number is (571) 272-0797. The Examiner can normally be reached Monday -Thursday from 8:00AM to 5:30PM and every other Friday from 9:00AM to 5:00 PM . Before and after final responses should be directed to fax nos. (703) 872-9306 and (703) 872-9307, respectively.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Dr. Amy Nelson, can be reached at (571) 272-0804.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Medeira A. MoVal

Mai

2/4/05

PATENT EXAMINER